NCT03965689 - Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 16, 2020

Primary Completion Date

September 7, 2022

Study Completion Date

March 18, 2026

Conditions

Metastatic Lung Non-Small Cell Squamous CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaStage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Unresectable Lung Non-Small Cell CarcinomaUnresectable Lung Non-Squamous Non-Small Cell Carcinoma

Interventions

DRUG

Carboplatin

Given IV

DRUG

Paclitaxel

Given IV

DRUG

Pevonedistat

Given IV

Trial Locations (10)

20007

MedStar Georgetown University Hospital, Washington D.C.

33607

Moffitt Cancer Center-International Plaza, Tampa

33612

Moffitt Cancer Center - McKinley Campus, Tampa

Moffitt Cancer Center, Tampa

43210

Ohio State University Comprehensive Cancer Center, Columbus

53792

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

90033

Los Angeles General Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

92663

USC Norris Oncology/Hematology-Newport Beach, Newport Beach

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH